drugset / Trial / NCT06892431
JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a randomized, open-label, multicenter Phase II clinical study, with the objective to assess the efficacy and safety of JMT101 Injection combined with Mitoxantrone Hydrochloride Liposome Injection in patients with recurrent/metastatic nasopharyngeal cancer who have failed at least two prior lines of treatment.
Timeline
- Start
- 2025-04-01
- Primary completion
- 2025-12-31
- Completion
- 2027-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BECOTATUG | Monoclonal antibody | 6 mg/kg | Intravenous |
| Comparator | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Mitoxantrone | Small molecule | 16 mg/m2 | Intravenous |
| Subject | Mitoxantrone | Small molecule | 20 mg/m2 | Intravenous |